Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
The development of a portfolio of SARS-CoV-2 vaccines to vaccinate the global population remains an urgent public health imperative. Here, we demonstrate the capacity of a subunit vaccine under clinical development, comprising the SARS-CoV-2 Spike protein receptor binding domain displayed on a two-component protein nanoparticle (RBD-NP), to stimulate robust and durable neutralizing antibody (nAb) responses and protection against SARS-CoV-2 in non-human primates. We evaluated five different adjuvants combined with RBD-NP including Essai O/W 1849101, a squalene-in-water emulsion; AS03, an alpha-tocopherol-containing squalene-based oil-in-water emulsion used in pandemic influenza vaccines; AS37, a TLR-7 agonist adsorbed to Alum; CpG 1018-Alum (CpG-Alum), a TLR-9 agonist formulated in Alum; or Alum, the most widely used adjuvant. All five adjuvants induced substantial nAb and CD4 T cell responses after two consecutive immunizations. Durable nAb responses were evaluated for RBD-NP/AS03 immunization and the live-virus nAb response was durably maintained up to 154 days post-vaccination. AS03, CpG-Alum, AS37 and Alum groups conferred significant protection against SARS-CoV-2 infection in the pharynges, nares and in the bronchoalveolar lavage. The nAb titers were highly correlated with protection against infection. Furthermore, RBD-NP when used in conjunction with AS03 was as potent as the prefusion stabilized Spike immunogen, HexaPro. Taken together, these data highlight the efficacy of the RBD-NP formulated with clinically relevant adjuvants in promoting robust immunity against SARS-CoV-2 in non-human primates.
Article activity feed
-
SciScore for 10.1101/2021.02.10.430696: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: Animals were housed and maintained as per National Institutes of Health (NIH) guidelines at the New Iberia Research Center (NIRC) of the University of Louisiana at Lafayette in accordance with the rules and regulations of the Committee on the Care and Use of Laboratory Animal Resources. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Animal subjects and experimentation: Thirty-three male rhesus macaques (Macaca mulatta) of Indian origin, aged 3 - 9 years were assigned to the study (Supplementary Table 1). Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources In wells with … SciScore for 10.1101/2021.02.10.430696: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: Animals were housed and maintained as per National Institutes of Health (NIH) guidelines at the New Iberia Research Center (NIRC) of the University of Louisiana at Lafayette in accordance with the rules and regulations of the Committee on the Care and Use of Laboratory Animal Resources. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Animal subjects and experimentation: Thirty-three male rhesus macaques (Macaca mulatta) of Indian origin, aged 3 - 9 years were assigned to the study (Supplementary Table 1). Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources In wells with anti-human IgG capture antibody, human IgG control (SinoBiological, #HG1K) was serially diluted from 0.5-500 ng/mL in TBST in triplicate and 50 μL of each dilution incubated for 1 h. anti-human IgGsuggested: NoneThe antibody-virus mixture was added to VeroE6 cell (C1008, ATCC, #CRL-1586 C1008suggested: Noneassay: Antibodies blocking the binding of SARS-CoV-2 Spike RBD to the angiotensin-converting enzyme 2 (ACE2) were detected with a V-PLEX SARS-CoV-2 Panel 2 (ACE2) Kit (Meso Scale Diagnostics) according to the manufacturer’s instructions. ACE2suggested: NoneLuminex Isotype and FcR Binding Assay: To determine relative concentrations of antigen-specific antibody isotypes and Fc receptor binding activity, a Luminex isotype assay was performed as previously described39. antigen-specificsuggested: NoneMouse-anti-rhesus antibody detectors were then added for each antibody isotype (IgG1, IgG2, IgG3, IgG4, IgA, NIH Nonhuman Primate Reagent Resource supported by AI126683 and OD010976). IgG1 , IgG2suggested: NoneIgG3 , IgG4suggested: NoneTertiary anti-mouse-IgG detector antibodies conjugated to PE were then added. anti-mouse-IgG detectorsuggested: NoneSystems serology: To quantify antibody functionality of plasma samples, bead-based assays were used to measure antibody-dependent cellular phagocytosis (ADCP), antibody-dependent neutrophil phagocytosis (ADNP) and antibody-dependent complement deposition (ADCD), as previously described40-43. antibody-dependent neutrophil phagocytosis ( ADNPsuggested: Noneantibody-dependent complement deposition ( ADCD)suggested: NoneSARS-CoV-2 spike protein (Hexapro antigen from Erica Ollmann Saphire, La Jallo for Immunology) was coupled to fluorescent streptavidin beads (Thermo Fisher) and incubated with sera samples to allow antibody binding to occur. SARS-CoV-2 spike protein ( Hexapro antigen from Erica Ollmann Saphire , La Jallo for Immunology )suggested: NoneSARS-CoV-2 spike protein ( Hexapro antigen from Erica Ollmann Saphire ,suggested: NoneAfter phagocytosis of immune complexes, neutrophils were stained with an anti-CD66b Pacific Blue detection antibody (Biolegend) prior to flow cytometry. anti-CD66bsuggested: NoneFor quantification of antibody-dependent NK cell activation, diluted plasma samples were incubated in Nunc MaxiSorp plates (Thermo Fisher Scientific) coated with antigen. antigen .suggested: NoneExperimental Models: Cell Lines Sentences Resources Anti-S binding ELISA: SARS-CoV-2 Spike protein was produced in HEK293T cells (Atum, Newark, CA) HEK293Tsuggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)For neutralization assays, HEK-hACE2 cells were cultured in DMEM with 10% FBS (Hyclone) and 1% PenStrep with 8% CO2 in a 37°C incubator on poly-lysine (sigma) 96 well plates. HEK-hACE2suggested: NonePseudovirions were produced in HEK293T/17 cells by co-transfection of a lentivirus backbone plasmid, a Spike-expressing plasmid, and a firefly Luc reporter gene plasmid. HEK293T/17suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)The furin cleavage site, a site with frequent culture adaptation in Vero E6 cells, harbored no polymorphisms at greater than 1% of sequence reads in this stock. Vero E6suggested: RRID:CVCL_XD71)For ADCP, cultured human monocytes (THP-1 cell line) were incubated with immune complexes, during which phagocytosis occurred. THP-1suggested: CLS Cat# 300356/p804_THP-1, RRID:CVCL_0006)Software and Algorithms Sentences Resources Animals were housed and maintained as per National Institutes of Health (NIH) guidelines at the New Iberia Research Center (NIRC) of the University of Louisiana at Lafayette in accordance with the rules and regulations of the Committee on the Care and Use of Laboratory Animal Resources. NIRCsuggested: NoneAlum (Alhydrogel 2%) was purchased from Croda Healthcare (Batch #0001610348). Croda Healthcaresuggested: NonePlates were immediately read at 450 nm on a SpectraMax M5 plate reader (Molecular Devices) and data plotted and fit in Prism (GraphPad) using nonlinear regression sigmoidal, 4PL, X is log(concentration) to determine EC50 values from curve fits. Prismsuggested: (PRISM, RRID:SCR_005375)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)All flow cytometry data were analyzed using Flowjo software v10 (TreeStar Inc.) Flowjosuggested: (FlowJo, RRID:SCR_008520)Before analysis, the PET images were Gaussian smoothed in OsiriX and smoothing was applied to raw data with a 3 x 3 matrix size and a matrix normalization value of 24. OsiriXsuggested: NonePET quantification values were organized in Microsoft Excel. Microsoft Excelsuggested: (Microsoft Excel, RRID:SCR_016137)All the statistical analyses were performed using GraphPad Prism v.9.0.0 or R version 3.6.1. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from scite Reference Check: We found no unreliable references.
-
